Submitted by Adriana Martinez (amartinez@unoeste.br) on 2017-12-18T11:39:51Z No. of bitstreams: 1 Rivaldo Marini Filho.pdf: 197818 bytes, checksum: ae8b3afee2f83011a3937b0b0a8b0124 (MD5) / Made available in DSpace on 2017-12-18T11:39:51Z (GMT). No. of bitstreams: 1 Rivaldo Marini Filho.pdf: 197818 bytes, checksum: ae8b3afee2f83011a3937b0b0a8b0124 (MD5) Previous issue date: 2011-09-26 / This study aimed to evaluate hematological and hemostatic parameters, cardiac and hepatic biomarkers in healthy dogs submitted to therapy with non-selective (NSAID) and COX-2 preferential nonsteroidal anti-inflammatory drugs. Were used 24 healthy dogs, randomly divided into 4 groups (G) submitted to therapy with ketoprofen, nimesulide, meloxicam and etodolac. The blood count, hemostatic profile (clotting time (CT), prothrombin time (PT), activated partial thromboplastin time (APTT), platelets and fibrinogen), cardiac biomarkers (CK, CKMB) and liver function (ALT, AST and albumin) were evaluate before, at 5 and 10 days (T0, T5, T10) of treatment. Were observed increase in CT in the ketoprofen and nimesulide groups at T5 and T10, respectivelly, when compared to T0. The etodolac group showed reduction in TP in T5 compared to T0. The platelet count increased at T10 compared to T0 and T5 in the ketoprofen group. The red blood cells and hematocrit decreased in at T10 in the ketoprofen group. Reduction of serum albumin occurred in the ketoprofen (T5 and T10) and nimesulide (T10) groups. In conclusion, meloxican was the safest drug to NSAID therapy in dogs. The NSAIDs ketoprofen, nimesulide and etodolac should be used judiciously in patients with dysfunction of coagulation profile, once that promote increase in coagulation parameters. Ketoprofen therapy requires attention for use in anemic dogs because they are able to reduce the red series, and in patients with hypoalbuminemia is contraindicated. / O presente estudo teve como objetivo avaliar a hemograma, hemostasia, biomarcadores cardíacos e função hepática de cães saudáveis tratados com anti-inflamatórios não-esteroidais (AINEs) não seletivos e COX-2 preferenciais. Foram utilizados 24 cães clinicamente sadios, divididos em 4 grupos (G), que receberam as seguintes terapias: cetoprofeno, nimesulida, meloxicam, e etodolaco, durante 10 dias. O hemograma, perfil hemostático (tempo de coagulação (TC), tempo de protrombina (TP), tempo de tromboplastina parcial ativada (TTPA), plaquetas e fibrinogênio), biomarcadores cardíacos (creatinofosfoquinase (CK) e sua fração MB- CKMB) e função hepática (alanina aminotransferase (ALT), aspartato aminotransferase (AST) e albumina foram avaliados antes, aos 5 e 10 dias (T0, T5 e T10) de tratamento. O TC revelou aumento significativo nos grupos cetoprofeno e nimesulida no T5 e T10, respectivamente, em relação ao T0. O grupo etodolaco revelou redução do TP no T5 em relação ao T0. A contagem de plaquetas aumentou no T10 em relação ao T0 e T5 no grupo cetoprofeno. As hemáceas e o Ht diminuiram no T10 no grupo cetoprofeno. Redução da albumina sérica ocorreu nos grupos cetoprofeno (T5 e T10) e nimesulida (T10). Em conclusão, o meloxican foi o fármaco que se revelou mais seguro para uso em cães, em relação aos aspectos avaliados. Os AINEs cetoprofeno, nimesulida e etodolaco devem ser usados criteriosamente em pacientes com disfunções do perfil de coagulação, uma vez que prolongam do mesmo. O cetoprofeno exige atenção para uso em cães anêmicos, pois é capaz de reduzir a série vermelha, e em pacientes com hipoalbuminemia é contra-indicado.

Acute coronary syndrome (ACS) refers to a group of clinical conditions caused by myocardial ischemia including unstable angina, non-ST-segment elevation myocardial infarction (NSTEMI), and ST-segmcnt elevation myocardial infarction (STEMI). Appropriate and accurate diagnosis has life-saving implications and requires a quick but thorough evaluation of the patient's history, physical examination, electrocardiogram, radiographic studies, and cardiac biomarkers. The management of patients with suspected or confirmed ACS continues to evolve as new evidence from clinical trials is considered and as new technology becomes available to both primary care physicians and cardiologists. Low- and intermediate-risk patients have frequently been managed in a chest pain center or in the emergency department. While stress testing with or without radionuclide imaging is the most common evaluation method, a CT angiogram is sometimes substituted High-risk patients are often managed with an early invasive strategy involving left heart catheterization with a goal of prompt revascularization of at-risk, viable myocardium. With the increased availability of cardiac catheterization facilities, patients with STEMI are more commonly being managed with primary percutaneous coronary intervention, although thrombolysis is still used where such facilities are not immediately available. This article provides primary care physicians with a concise review of the pathophysiology, clinical evaluation, and management of ACS based on the best available evidence in 2008.

Background: Surgical procedures are invariably accompanied by the use of inhalational and intravenous anesthetics. Both groups have strong influence on cardiovascular system by the interaction with myocardial oxygen supply/demand ratio and cardiomyocyte functions at the level of cell membranes, ion channels and regulatory enzymes. Aims: 1. To examine the effects of different isoflurane concentrations on the left ventricular (LV) dimensions and systolic function in the rat. 2. To examine the effects of isoflurane-induced myocardial preconditioning (APC) on the cardiac tolerance to ischemia- reperfusion (I-R) injury. 3. To compare the influence of anesthesia, based on ketamine- dexmedetomidine (KET-DEX), on the release of biochemical markers of myocardial injury and the early postoperative course with the anesthesia, based on sevoflurane-sufentanil (SEVO), in the patients undergoing coronary artery bypass grafting (CABG). Methods: 1. We carried out transthoracic echocardiographic examination in the rats immobilized by 1.5-3% concentration of isoflurane. 2. After inducing APC by isoflurane (0.5 and 1 MAC), we evaluated ventricular arrhythmias during regional ischemia (45 min), induced by the occlusion of the left anterior descending artery, and subsequent reperfusion (60 min), using the model of...

Background: Surgical procedures are invariably accompanied by the use of inhalational and intravenous anesthetics. Both groups have strong influence on cardiovascular system by the interaction with myocardial oxygen supply/demand ratio and cardiomyocyte functions at the level of cell membranes, ion channels and regulatory enzymes. Aims: 1. To examine the effects of different isoflurane concentrations on the left ventricular (LV) dimensions and systolic function in the rat. 2. To examine the effects of isoflurane-induced myocardial preconditioning (APC) on the cardiac tolerance to ischemia- reperfusion (I-R) injury. 3. To compare the influence of anesthesia, based on ketamine- dexmedetomidine (KET-DEX), on the release of biochemical markers of myocardial injury and the early postoperative course with the anesthesia, based on sevoflurane-sufentanil (SEVO), in the patients undergoing coronary artery bypass grafting (CABG). Methods: 1. We carried out transthoracic echocardiographic examination in the rats immobilized by 1.5-3% concentration of isoflurane. 2. After inducing APC by isoflurane (0.5 and 1 MAC), we evaluated ventricular arrhythmias during regional ischemia (45 min), induced by the occlusion of the left anterior descending artery, and subsequent reperfusion (60 min), using the model of...